Month: September 2025

CGM commercial operations to transition from Ascensia Diabetes Care to Senseonics Brian Hansen to be appointed Chief Commercial Officer Non-dilutive debt facility expanded up to $100 million with Hercules Capital to fund commercial organization Conference Call scheduled for September 4, 2025 at 8:00 A.M. Eastern Time GERMANTOWN, Md., Sept. 03, 2025 (GLOBE NEWSWIRE) — Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced a mutually executed Memorandum of Understanding to transition all commercialization and distribution of Eversense 365 and future products from Ascensia Diabetes Care, a member of PHC Group, to Senseonics. Since 2020, Ascensia has held...

This news release constitutes a “designated news release” for the purposes of CAPREIT’s prospectus supplement dated May 15, 2025, to its short form base shelf prospectus dated May 15, 2025. TORONTO, Sept. 03, 2025 (GLOBE NEWSWIRE) — Canadian Apartment Properties Real Estate Investment Trust (“CAPREIT”) (TSX: CAR.UN) announced today that since the second quarter of 2025, it has closed on, or has entered into agreements to close on, the acquisition of five strategically aligned rental apartment properties in Canada for an aggregate purchase price of $214.0 million. CAPREIT also announced that it has closed on two non-core Canadian dispositions for combined gross proceeds of $82.5 million. All amounts disclosed herein exclude transaction costs and other customary adjustments. So far in the third quarter of 2025, CAPREIT has completed...

TORONTO, Sept. 03, 2025 (GLOBE NEWSWIRE) — Altai Resources Inc. (TSXV: ATI) (“Altai” or the “Company”) announced that at today’s special meeting (the “Meeting”) of shareholders of the Company (the “Shareholders”), the Shareholders approved, with approximately 96.4% of the votes cast in favor of, a special resolution (the “Stated Capital Reduction Resolution”) authorizing and approving a reduction of the stated capital account of the common shares of the Company (the “Common Shares”) by an aggregate amount to be determined by the board of directors of the Company from time to time up to a maximum cumulative total amount of $4,000,000 pursuant to Section 34(1)(b) of the Business Corporations Act (Ontario) for the purposes of distributing such amount to holders of Common Shares by way of a return of capital in one or more special...

HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences:H.C. Wainwright 27th Annual Global Investment ConferenceDate: Tuesday, September 9, 2025Format: 1×1 Investor Meetings Only   Morgan Stanley 23rd Annual Global Healthcare Conference Date: Wednesday, September 10, 2025Format: Fireside Chat Time: 2:35 PM – 3:10 PM EST and 1×1 Investor Meetings   About vTv TherapeuticsvTv Therapeutics is a late-stage biopharmaceutical company focused on developing...

MONTEVIDEO, Uruguay, Sept. 03, 2025 (GLOBE NEWSWIRE) — DLocal Limited (“dLocal” or the “Company”), (NASDAQ:DLO) a technology-first payments platform, today announced the commencement of an underwritten registered secondary offering of 15,000,000 Class A common shares by an entity associated with General Atlantic (the “Selling Shareholder”). The Company is not selling any Class A common shares in the offering and will not receive any proceeds from the offering. In connection with the offering, the Selling Shareholder expects to grant the underwriters a 30-day option to purchase up to an additional 2,250,000 Class A common shares at the public offering price, less underwriting discounts and commissions. The offering is being made through an underwriting group led by J.P. Morgan, Goldman Sachs & Co. LLC and Morgan Stanley, who...

DALLAS, Sept. 03, 2025 (GLOBE NEWSWIRE) — P10, Inc. (NYSE: PX), a leading private markets solutions provider, today announced that Chairman and Chief Executive Officer, Luke Sarsfield, and EVP and Chief Administrative Officer, Mark Hood, will participate in a fireside chat at the Barclays 23rd Annual Global Financial Services Conference on Monday, September 8, 2025, scheduled for 12:00 P.M. Eastern Time. A webcast of the discussion will be available on the Investor Relations section of P10’s website at ir.p10alts.com/events. For those unable to listen to the live webcast, a replay will be available on the Events page of P10’s website by the end of the same day. About P10P10 (NYSE: PX) is a leading private markets solutions provider with over $40 billion in assets under management as of June 30, 2025. P10 invests across Private...

SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced it has commenced an underwritten public offering of its common stock and/or pre-funded warrants. All shares of common stock and/or pre-funded warrants in the offering are to be offered by the Company. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. R.F. Lafferty & Co., Inc. is acting as the sole book-running manager for the offering. The shares of common stock and/or pre-funded warrants are being offered...

Châtillon, France, September 3, 2025 DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025, at 11:30am ET, in New York, NY. A live webcast of the fireside chat can be accessed here, and will also be available on the Events section of the Company’s Investors website: https://dbv-technologies.com/investor-overview/events/, with an archived replay accessible for 90 days following the event. About DBV TechnologiesDBV Technologies is a clinical-stage biopharmaceutical company...